HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report.

Abstract
In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option.
AuthorsEvangéline Pillebout, Fabiane Rocha, Laurence Fardet, Michel Rybojad, Jérôme Verine, Denis Glotz
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 26 Issue 6 Pg. 2044-6 (Jun 2011) ISSN: 1460-2385 [Electronic] England
PMID21436378 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab
Topics
  • Adult
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Humans
  • IgA Vasculitis (drug therapy)
  • Immunologic Factors (therapeutic use)
  • Immunomodulation
  • Male
  • Rituximab
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: